Expressão dos antígenos Ki-67, Bcl-2 e Bax no carcinoma de mama de mulheres tratadas com raloxifeno / Expression of Ki-67 antigen, Bcl-2 and Bax in breast carcinoma of women treated with raloxifene

AUTOR(ES)
FONTE

IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia

DATA DE PUBLICAÇÃO

25/09/2009

RESUMO

Background: Breast cancer endocrinotherapy is one of the most important therapeutic strategies. Nevertheless, in spite of the positivity estrogen receptor, not always there is a good response. Therefore, there is a great interest of the researchers in finding biomarkers to evaluate the prognostic, and predict therapeutic responses. Objective: The aim of this study was to evaluate the effect of raloxifene on Ki-67, Bcl-2 and Bax expression in estrogen-receptorpositive invasive ductal breast carcinomas. Patients and Methods: Twenty postmenopausal women who had taken 60 mg of raloxifene daily for 28 days prior to definitive surgery were enrolled in the study. Two tumor samples were obtained by incisional biopsy during the study, one at the time of confirmation of the diagnosis of invasive ductal carcinoma and evaluation of estrogen receptor status, and the other 29 days later, at the time of definitive surgery. Immunohistochemistry was performed in tumor samples prior to and following raloxifene treatment to evaluate Ki-67, Bcl-2 and Bax expression. The Friedman and McNemar tests were used in the statistical analysis of the data, significance being established at 5%. Results: The mean percentage of Ki-67-stained nuclei was 24.86 2.95 prior to raloxifene treatment and 13.33 1.52 following treatment (p<0.001). Prior to raloxifene treatment, only 9/20 cases (45%) were classified as Bcl-2-positive, whereas following treatment 17/20 (85%) were classified as Bcl-2-positive (p<0.013). With respect to Bax expression, eleven of the 20 patients (55%) were classified as positive for Bax expression prior to raloxifene treatment, while 9(45%) were classified as positive following raloxifene treatment (p=0.479) Conclusion: The raloxifene treatment significantly reduced Ki-67 antigen expression, increased Bcl-2 expression and did not alter Bax expression in estrogen receptor-positive breast carcinomas of postmenopausal women.

ASSUNTO(S)

câncer de mama serms raloxifeno ki-67 bcl-2 bax medicina breast cancer serms raloxifene ki-67 bcl-2. bax

ACESSO AO ARTIGO

Documentos Relacionados